Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Clarithromycin × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 4 Stomach Neoplasms 3 Peptic Ulcer 2 Gastritis 2 Dyspepsia 2 Recurrence 1 Lymphoma, B-Cell, Marginal Zone 1 Helicobacter Infections 1 Chemotherapy Effect 1 Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 37 venetoclax 27 fludarabine 27 Dexamethasone 27 pembrolizumab 20 Rituximab 17 Gemcitabine 16 pomalidomide 15 Cytarabine 14 Lenalidomide 13 Nivolumab 11 fludarabine phosphate 10 carfilzomib 10 Temozolomide 10 Etoposide 10 Calcium Dobesilate 10 Azacitidine 10 Injections 9 obinutuzumab 8 glofitamab 8 daratumumab 8 cemiplimab 7 Cisplatin 7 Capecitabine 7 Bevacizumab 7 zanubrutinib 6 selinexor 6 ruxolitinib 6 ibrutinib 6 Decitabine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02343042 2025-12-22

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡